Strongbridge Biopharma plc (SBBP)

Strongbridge Biopharma plc (SBBP) Healthcare & Pipeline Overview

Strongbridge Biopharma plc specializes in developing innovative therapies for rare diseases, leveraging its expertise in biopharmaceuticals to address significant unmet medical needs, particularly in the treatment of conditions like hyperkalemic periodic paralysis and Cushing's syndrome.

What Is the Investment Thesis for SBBP?

Strongbridge Biopharma plc presents a compelling investment thesis driven by its unique product offerings and a robust pipeline targeting rare diseases. The company’s flagship product, Keveyis, has established a foothold in the market, while Recorlev’s ongoing Phase III trials could significantly enhance revenue potential upon successful approval. The global market for Cushing's syndrome treatments is projected to grow significantly, providing a substantial opportunity for Strongbridge. Additionally, the high gross margin of 92.8% indicates a strong pricing power and operational efficiency. However, the company faces risks associated with clinical trial outcomes and market competition, which could impact its growth trajectory. The combination of these factors positions Strongbridge for potential growth, contingent on successful clinical developments and market acceptance.

Based on FMP financials and quantitative analysis

SBBP Key Highlights

• Profit margin of -146.7% reflects the company's current investment phase in research and development.
• Gross margin of 92.8% indicates strong pricing power and operational efficiency in its product offerings.
• Beta of 1.60 suggests higher volatility compared to the market, highlighting potential investment risks.
• Strongbridge Biopharma has no dividend yield, focusing all resources on growth and development.
• The company has a focused workforce of 72 employees, allowing for agile decision-making and operational flexibility.

Who Are SBBP's Competitors?

SBBP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SBBP's Key Strengths?

• Strong gross margin of 92.8% indicating high profitability potential.
• Established product, Keveyis, providing immediate revenue.
• Focused expertise in rare diseases with a dedicated pipeline.
• Experienced management team with a strong track record in pharmaceuticals.

What Are SBBP's Weaknesses?

• Negative profit margin of -146.7% highlighting ongoing investment in R&D.
• Limited product portfolio with reliance on a single revenue-generating product.
• Small workforce may limit operational scalability and market reach.
• High volatility indicated by a beta of 1.60, posing investment risks.

What Could Drive SBBP Stock Higher?

• Results from Phase III clinical trials for Recorlev expected in Q4 2026, which could drive significant revenue growth if successful.
• Continued sales growth of Keveyis as awareness and diagnosis of periodic paralysis increase in the U.S.
• Potential partnership announcements to enhance product development and market access in 2026.
• Advancements in the clinical pipeline with Veldoreotide progressing towards potential Phase III trials.
• Regulatory updates regarding clinical trials that may impact timelines and market strategies.

What Are the Key Risks for SBBP?

• Negative return on equity (-65.4%) — the business is not currently generating profit on shareholder capital.
• Clinical trial failures for Recorlev and Veldoreotide could hinder product approvals and revenue growth.
• Market competition from larger biopharmaceutical companies could impact market share and pricing power.
• Regulatory challenges could delay product launches and increase development costs.
• Dependence on a limited product portfolio increases vulnerability to market fluctuations.

What Are the Growth Opportunities for SBBP?

• Growth opportunity 1: Strongbridge Biopharma's Recorlev, currently in Phase III trials for endogenous Cushing's syndrome, represents a significant growth driver. The global market for Cushing's syndrome treatments is estimated to reach $1.2 billion by 2025, driven by increasing awareness and diagnosis rates. Successful approval could position Strongbridge as a key player in this lucrative market.
• Growth opportunity 2: The expanding market for treatments of rare diseases is a major opportunity for Strongbridge. With over 7,000 rare diseases affecting approximately 30 million people in the U.S. alone, the demand for effective therapies continues to rise. Strongbridge's focus on rare diseases allows it to tap into a market projected to grow at a CAGR of 12.8% through 2027, enhancing its revenue potential.
• Growth opportunity 3: Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly, presents another avenue for growth. The global acromegaly market is expected to reach $1.1 billion by 2026, driven by increased diagnosis and treatment rates. If Veldoreotide successfully advances through clinical trials, it could significantly contribute to Strongbridge's revenue.
• Growth opportunity 4: Strategic partnerships and collaborations with other biopharmaceutical companies could enhance Strongbridge's research capabilities and market reach. Collaborating with larger firms may provide access to additional resources and expertise, accelerating the development of its pipeline products and expanding its market presence.
• Growth opportunity 5: The increasing focus on personalized medicine and targeted therapies in the biotechnology sector aligns with Strongbridge's mission. As healthcare shifts towards more tailored treatment approaches, Strongbridge's innovative therapies for rare diseases position it well to capitalize on this trend, potentially leading to increased market share and revenue growth.

What Opportunities Does SBBP Have?

• Growing market for rare disease treatments, projected to expand significantly.
• Potential for successful product launches from clinical pipeline candidates.
• Strategic partnerships could enhance R&D capabilities and market access.
• Increasing focus on personalized medicine aligns with Strongbridge's mission.

What Threats Does SBBP Face?

• Risks associated with clinical trial outcomes that may delay product approvals.
• Intense competition from larger biopharmaceutical companies in the rare disease space.
• Potential regulatory challenges impacting product development timelines.
• Market acceptance risks for new therapies in a niche segment.

What Are SBBP's Competitive Advantages?

• Strong gross margins of 92.8% provide a competitive edge in pricing and profitability.
• Focus on rare diseases creates a niche market with limited competition.
• Established product, Keveyis, provides a revenue-generating asset while further products are developed.
• Expertise in clinical trials and regulatory processes enhances the company's ability to bring new therapies to market.
• Strong relationships with key opinion leaders in the rare disease community bolster credibility and market presence.

What Does SBBP Do?

Founded in 1996 and headquartered in Trevose, Pennsylvania, Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of therapies for rare diseases that lack effective treatments. Originally established as Cortendo plc, the company rebranded in September 2015 to reflect its renewed focus on rare diseases. Strongbridge's flagship product, Keveyis, is an oral carbonic anhydrase inhibitor approved for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. This product highlights the company's commitment to addressing critical healthcare needs in niche markets. In addition to Keveyis, Strongbridge is advancing its clinical pipeline, which includes Recorlev, a cortisol synthesis inhibitor currently in Phase III clinical trials for the treatment of endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. With a workforce of 72 employees, Strongbridge Biopharma is strategically positioned to leverage its innovative product offerings and clinical expertise to capture market share in the rare disease segment, which is characterized by high unmet medical needs and limited competition.

What Products and Services Does SBBP Offer?

• Develops and commercializes therapies for rare diseases with unmet medical needs.
• Offers Keveyis, an oral carbonic anhydrase inhibitor for treating specific types of periodic paralysis.
• Advances clinical-stage candidates like Recorlev and Veldoreotide for rare endocrine disorders.
• Focuses on addressing significant healthcare gaps in the rare disease segment.
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
• Engages with healthcare professionals and stakeholders to promote awareness of rare diseases.

How Does SBBP Make Money?

• Generates revenue through the sale of its approved product, Keveyis.
• Invests in research and development to advance its clinical pipeline and bring new therapies to market.
• Collaborates with healthcare providers and institutions to enhance product visibility and adoption.
• Utilizes a direct sales approach to reach healthcare professionals and patients effectively.
• Seeks partnerships with other biopharmaceutical companies to expand its product offerings and market access.

What Industry Does SBBP Operate In?

The biotechnology industry is experiencing significant growth, driven by advancements in technology and an increasing focus on personalized medicine. The global biotechnology market is expected to reach approximately $2.44 trillion by 2028, with a CAGR of 15.83% from 2021 to 2028. Within this context, Strongbridge Biopharma plc is strategically positioned in the rare disease segment, which is characterized by a high demand for innovative treatments and limited competition. The company's focus on rare diseases aligns with industry trends that prioritize addressing unmet medical needs, making it a relevant player in the evolving biotechnology landscape.

Who Are SBBP's Key Customers?

• Patients diagnosed with rare diseases requiring specialized treatments.
• Healthcare providers and specialists in rare disease management.
• Hospitals and clinics that administer treatments for rare conditions.
• Pharmaceutical distributors and pharmacy benefit managers involved in drug distribution.
• Research institutions focusing on rare diseases and innovative therapies.

ROE -65%Key Financial Metrics

Return on equity for Strongbridge Biopharma plc stands at -65.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -37.2%, showing how much profit it generates from its asset base. A current ratio of 4.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -40.2%, the inverse of the P/E and a quick read on earnings relative to price.

Strongbridge Biopharma plc (SBBP) Valuation Context

Relative to its peer group, SBBP's quantitative score of 61/100 is roughly in line with the peer average of 68/100.

Company Profile

Strongbridge Biopharma plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Trevose, US. The company is led by CEO Matthew Pauls. SBBP has traded publicly since 2015.

SBBP Financials

SBBP Latest News

SBBP Analyst Consensus

SBBP MoonshotScore

What Investors Ask About Strongbridge Biopharma plc (SBBP) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources